{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:55:55Z","timestamp":1791327355716,"version":"4.3.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) have shown efficacy in the treatment of migraine. However, certain comorbidities have been excluded from clinical trials or may pose potential risks, despite not being formal contraindications. This study aimed to assess the safety of anti-CGRP or anti-CGRP receptor mAbs in real-world patients with such conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective multicenter study was conducted across 11 headache units in Spain. Patients with relevant or trial-excluded comorbidities who received at least one anti-CGRP or anti-CGRP receptor mAb were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 2,042 evaluated patients, 353 had at least one comorbidity. The mean treatment duration was 12.7\u202fmonths [standard deviation (SD)\u202f=\u202f8\u202fmonths]. A total of 53 conditions were included: 202 had autoimmune diseases, 163 presented vascular risk factors or diseases [body mass index (BMI)\u202f&amp;gt;\u202f30: 15.2%, diabetes: 5.38%, stroke\/transient ischemic attack (TIA): 3.08%, cardiac ischaemic disease: 1.44%], of which 23 had moderate-to-high cardiovascular risk (Framingham scale); 23 had pulmonary diseases, 71 had a history of cancer, 12 were immunosuppressed, and 16 had other conditions. In 12% of cases, disease control was suboptimal after treatment initiation, without a causal relationship to the mAb. A possible treatment-related worsening was observed in 14 cases: four with arterial hypertension worsening, seven with Raynaud\u2019s syndrome, two with arthritis flares, and one hereditary angioedema; all improved upon treatment discontinuation. No severe adverse events were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In this study, treatment with monoclonal antibodies acting on the CGRP pathway showed a favorable safety profile in patients with complex clinical conditions not represented in clinical trials, with no serious adverse events observed during extended follow-up. These findings support their use in real-world clinical settings, although further studies are needed to confirm their long-term safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1703876","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T05:16:31Z","timestamp":1764134191000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["SAFE-CGRP study: multicenter retrospective evaluation of the safety of CGRP pathway\u2013targeting monoclonal antibodies in migraine with relevant comorbidities or conditions excluded from trials"],"prefix":"10.3389","volume":"16","author":[{"given":"Cristina","family":"Sanabria-Gago","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris Fern\u00e1ndez","family":"L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Heredia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"S\u00e1nchez-Soblechero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Lozano","family":"Ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa Luque","family":"Buzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesica Gonz\u00e1lez","family":"Osorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Guerrero-Peral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Gonzalez-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Garc\u00eda","family":"Azor\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germ\u00e1n","family":"Latorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Toledo-Alfocea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier Casas","family":"Lim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarai Urtiaga","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Gonz\u00e1lez","family":"Salaices","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo Mart\u00edn","family":"\u00c1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Terrero","family":"Carpio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Gonz\u00e1lez-Quintanilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Madera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Polanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Rodr\u00edguez-Vico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Jaimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea G\u00f3mez","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Luz","family":"Cuadrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Beatriz","family":"Gago-Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/head.14709","article-title":"Prevalence and burden of migraine in the United States: a systematic review","volume":"64","author":"Cohen","year":"2024","journal-title":"Headache"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","article-title":"Migraine: epidemiology and systems of care","volume":"397","author":"Ashina","year":"2021","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-018-0846-2","article-title":"Migraine is first cause of disability in under 50s: global burden of disease study 2017","volume":"19","author":"Steiner","year":"2018","journal-title":"J Headache Pain"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","article-title":"Migraine remains second among the world's causes of disability, and first among young women: findings from GBD 2019","volume":"21","author":"Steiner","year":"2020","journal-title":"J Headache Pain"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/bcp.12618","article-title":"CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment","volume":"80","author":"Edvinsson","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/B978-0-12-823357-3.00024-0","article-title":"CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention","volume":"199","author":"Caronna","year":"2024","journal-title":"Handb Clin Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/S0140-6736(19)32504-8","article-title":"Targeting calcitonin gene-related peptide: a new era in migraine therapy","volume":"394","author":"Charles","year":"2019","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1177\/0333102419829007","article-title":"Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine\u2014a meta-analysis of randomized controlled trials","volume":"39","author":"Xu","year":"2019","journal-title":"Cephalalgia"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e45560","DOI":"10.7759\/cureus.45560","article-title":"Efficacy and safety of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies in preventing migraines: a systematic review","volume":"15","author":"Muddam","year":"2023","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3331024231159366","DOI":"10.1177\/03331024231159366","article-title":"Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials","volume":"43","author":"Haghdoost","year":"2023","journal-title":"Cephalalgia"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"106893","DOI":"10.1016\/j.clineuro.2021.106893","article-title":"Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: a systematic review and network meta-analysis","volume":"209","author":"Soni","year":"2021","journal-title":"Clin Neurol Neurosurg"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","article-title":"Calcitonin gene-related peptide: physiology and pathophysiology","volume":"94","author":"Russell","year":"2014","journal-title":"Physiol Rev"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.4049\/jimmunol.165.8.4359","article-title":"Induction and expression of beta-calcitonin gene-related peptide in rat T lymphocytes and its significance","volume":"165","author":"Xing","year":"2000","journal-title":"J Immunol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1152\/physrev.00059.2021","article-title":"CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond","volume":"103","author":"Russo","year":"2023","journal-title":"Physiol Rev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1001\/jama.2018.4853","article-title":"Fremanezumab for prevention of migraine: a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Dodick","year":"2018","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","article-title":"Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"19","author":"Mulleners","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"833645","DOI":"10.3389\/fphys.2022.833645","article-title":"The vascular-dependent and -independent actions of calcitonin gene-related peptide in cardiovascular disease","volume":"13","author":"Argunhan","year":"2022","journal-title":"Front Physiol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s11916-022-01064-4","article-title":"Cardiovascular disease and migraine: are the new treatments safe?","volume":"26","author":"Robblee","year":"2022","journal-title":"Curr Pain Headache Rep"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.tips.2016.06.002","article-title":"Wiping out CGRP: potential cardiovascular risks","volume":"37","author":"MaassenVanDenBrink","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3331024241297673","DOI":"10.1177\/03331024241297673","article-title":"Impact of monoclonal CGRP antibody treatment on blood pressure in patients with migraine: a systematic review and potential clinical implications","volume":"45","author":"van der Arend","year":"2025","journal-title":"Cephalalgia"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.molmed.2020.10.005","article-title":"CGRP receptor antagonism in COVID-19: potential cardiopulmonary adverse effects","volume":"27","author":"Skaria","year":"2021","journal-title":"Trends Mol Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"663535","DOI":"10.3389\/fcell.2021.663535","article-title":"Neuroimmune pathophysiology in asthma","volume":"9","author":"Pav\u00f3n-Romero","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12967-020-02681-6","article-title":"Anti-migraine agents from an immunological point of view","volume":"19","author":"Assas","year":"2021","journal-title":"J Transl Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1212\/wnl.40.6.971","article-title":"Interrater variability with the expanded disability status scale (EDSS) and functional systems (FS) in a multiple sclerosis clinical trial","volume":"40","author":"Noseworthy","year":"1990","journal-title":"Neurology"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"ref28","volume-title":"CADTH health technology review","author":"Khangura","year":"2023"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index: national cooperative Crohn's disease study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"ref30","volume-title":"Framingham risk score. In: Medicine and dentistry","year":""},{"key":"ref31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S1131-3587(12)70067-5","article-title":"Diagn\u00f3stico y estratificaci\u00f3n de la angina estable","volume":"12","author":"Borr\u00e1s P\u00e9rez","year":"2012","journal-title":"Rev Esp Cardiol Suppl"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1378\/chest.93.3.580","article-title":"Evaluation of clinical methods for rating dyspnea","volume":"93","author":"Mahler","year":"1988","journal-title":"Chest"},{"key":"ref33","volume-title":"Global strategy for the prevention, diagnosis and management of chronic obstructive pulmonary disease: 2025 report","year":"2024"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","article-title":"Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study","volume":"95","author":"Goadsby","year":"2020","journal-title":"Neurology"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12883-021-02123-w","article-title":"Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial","volume":"21","author":"Kudrow","year":"2021","journal-title":"BMC Neurol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","article-title":"Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial","volume":"28","author":"Ashina","year":"2021","journal-title":"Eur J Neurol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e16450","DOI":"10.1111\/ene.16450","article-title":"Association of anti-calcitonin gene-related peptide with other monoclonal antibodies for different diseases: a multicenter, prospective, cohort study","volume":"31","author":"Annone","year":"2024","journal-title":"Eur J Neurol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3389\/fphys.2018.01249","article-title":"The role of calcitonin gene-related peptide (CGRP) in neurogenic vasodilation and its cardioprotective effects","volume":"9","author":"Kee","year":"2018","journal-title":"Front Physiol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1387044","DOI":"10.3389\/fneur.2024.1387044","article-title":"Safety considerations in the treatment with anti-CGRP(R) monoclonal antibodies in patients with migraine","volume":"15","author":"Van Der Arend","year":"2024","journal-title":"Front Neurol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1212\/WNL.0000000000008743","article-title":"Vascular safety of erenumab for migraine prevention","volume":"94","author":"Kudrow","year":"2020","journal-title":"Neurology"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/head.13684","article-title":"Evaluation of cardiovascular outcomes in adult patients with episodic or chronic migraine treated with galcanezumab: data from three phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies","volume":"60","author":"Oakes","year":"2020","journal-title":"Headache"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00415-025-13177-y","article-title":"Concomitant anti-CGRP and immunomodulatory treatments in patients with migraine: towards integrated management strategies","volume":"272","author":"Garc\u00eda-Castillo","year":"2025","journal-title":"J Neurol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-022-05374-w","article-title":"Nociceptor neurons affect cancer immunosurveillance","volume":"611","author":"Balood","year":"2022","journal-title":"Nature"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s10194-025-02040-0","article-title":"Increased infection risk in patients on preventive CGRP-targeting therapies\u2014a meta-analysis and clinical effect assessment","volume":"26","author":"Straburzy\u0144ski","year":"2025","journal-title":"J Headache Pain"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1703876\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T05:16:32Z","timestamp":1764134192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1703876\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":44,"alternative-id":["10.3389\/fneur.2025.1703876"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1703876","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"article-number":"1703876"}}